Hepalink Pharmaceutical revamps governance, appoints new independent director

Shenzhen Hepalink Pharmaceutical Group is undertaking a significant corporate restructuring, abolishing its board of supervisors and related positions. Oversight responsibilities will transfer to the board of directors' audit committee. This change, approved by the Sixth Board of Directors at its eighteenth meeting on November 24, 2025, requires revisions to the company's Articles of Association and various governance policies, including new "Financial Assistance to External Parties Management System" and "Management System for Departure of Directors and Senior Management."

Concurrently, Mr. Lü Chuan will resign as an independent director due to the expiration of his six-year term. The board has nominated Mr. Pu Hong as the new independent director, subject to shareholder approval and regulatory review. Mr. Pu Hong will also assume roles on the nomination, audit, and strategy committees.

These proposals, including the election of Mr. Pu Hong, will be presented for shareholder approval at the company's first extraordinary general meeting in 2025, scheduled for December 16, 2025, with online voting available.